Skip to content
"The programme showed us nothing new which we need to act on today," SEB Chief Executive Johan Torgeby told Reuters after SVT reported that an SEB client list contained "red flags" - names associated with well-known proxies for Russian non-resident companies suspected of money laundering. SEB had managed to stay clear of a long-running Baltic money scandal which has hit rivals Swedbank and Danske Bank. SVT's report said transactions through 194 SEB accounts included around 475 million Swedish crowns ($49 million) connected to the so-called Magnitsky affair....
Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be......
Gavin Graham is a specialist in international securities and has held senior positions in financial organizations in London, Hong Kong, and Toronto. Here, the contributing editor to Internet Wealth Builder reviews two recommendations among Canadian banks....
Strike a balance between checking too often and never at all....
Readers hoping to buy Saputo Inc. (TSE:SAP) for its dividend will need to make their move shortly, as the stock is......
(Bloomberg) -- Want the lowdown on European markets? In your inbox before the open, every day. Sign up here.Activist investor Elliott Management Corp. said that Capgemini SE’s offer for Altran Technologies SA is inadequate and called the sales process flawed.Elliott, which has built up a position of more than 10% in Altran, believes that a fair value for the company is more than 20 euros a share, based on analysts’ estimates for the company’s future earnings, it said in a statement on Wednesday. The firm had said in an earlier filing that Capgemini’s current offer of 14-euros-a-share, or 3.6 billion euros ($4 billion) excluding debt, undervalues the company.“Altran shareholders are offered an inadequate premium to forgo the company’s promising standalone prospects, despite the huge value-creation potential of the combination,’’ Elliott said in the statement.Altran shares rose 0.2% to 14.07 euros at 10:25 a.m. in Paris. The stock’s gained about 23% since...
Shareholders will be ecstatic, with their stake up 34% over the past week following Arrowhead Pharmaceuticals, Inc.'s......
